Brief: Ac Immune Progress Update On Phase 2 Active Immunotherapy Clinical Pipeline
03/01/2024 13:17
Jan 3 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE PROGRESS UPDATE ON PHASE 2 ACTIVE IMMUNOTHERAPY
CLINICAL PIPELINE FOR ALZHEIMER'S AND PARKINSON DISEASES
* FOLLOWING DATA SAFETY MONITORING BOARD REVIEW, NO SAFETY
CONCERNS HAVE BEEN RAISED TO DATE PHASE FOR 1B/2 TRIAL OF
ACI-24.060
Source text for Eikon: ID:nGNXcg5g8v
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture